Executives from Merck Pharmaceuticals met with all the scientist and other professionals involved in getting to market a new drug product, from discovery to product launch. The product is called sitagliptin and is known in the market by the trade names Januvia and Janumet, depending on the formulation and is used for the treatment of type II diabetes.
Among other topics they emphasized the role of innovation in pharmaceutical companies, despite recent budget cuts for Reasearch and Development departments in various multinationals. They also talked about the importance of science education at an early age for all, but specially for women.
***The original news story is in Spanish. To read the full text, please click on the "Español" button below or the link at the top right of the page.